Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Germ Cell Neoplasms Clear all

Conditions: Glioblastoma, Astrocytoma, Pineoblastoma, Rhabdoid Tumor, Supratentorial Neoplasms
Interventions: Stem Cell Transplant; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 18 Months to 25 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glioma, Glioblastoma
Interventions: Readiband Sleep Tracking; Device
Lead sponsor: Allina Health System; Other
Eligibility: 22 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Glioblastoma, Recurrent Glioblastoma, GBM
Interventions: SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide; Device · Drug
Lead sponsor: CarThera; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more

Conditions: Tumor, Metastatic Melanoma, Melanoma
Interventions: OBX-115, Acetazolamide, Cyclophosphamide, Furosemide, Mesna, Fludarabine Phosphate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Colon Cancer, Lung Cancer, Neuroblastoma, Testicular Cancer
Interventions: Focus Group Sessions; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: GINAKIT Cells, GINAKIT cells + Etanercept; Genetic · Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2040
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioma
Interventions: 5-Aminolevuline Acid (ALA); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 72 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Astrocytoma, Oligoastrocytoma, Oligodendroglioma
Interventions: Peptide vaccine + Poly-ICLC; Biological
Lead sponsor: Ian F. Pollack, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: RECURRENT GLIOBLASTOMA, Brain Tumor
Interventions: Optune(NOVOTTF-100A); Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 22 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
Interventions: TRC105, Bevacizumab; Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 16 Years to 99 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • Columbus, Ohio • Dallas, Texas

Conditions: Melanoma (Skin)
Interventions: bevacizumab, carboplatin, everolimus, paclitaxel; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 310
States / cities: Scottsdale, Arizona • Martinez, California • Mountain View, California + 214 more

Conditions: Brain and Central Nervous System Tumors
Interventions: temozolomide; Drug
Lead sponsor: Duke University; Other
Eligibility: 4 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions: Exercise Test; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions: ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis; Biological · Radiation · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glioblastoma, Gliosarcoma
Interventions: Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide; Other · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio

Conditions: High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
Interventions: Temsirolimus; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
Interventions: Polio/Rhinovirus Recombinant (PVSRIPO); Biological
Lead sponsor: Istari Oncology, Inc.; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma, GBM, Glioblastoma Multiforme
Interventions: Ascorbate, Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Recurrent Melanoma, Stage IV Skin Melanoma
Interventions: NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12, MART-1 Antigen, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ependymoma
Interventions: HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry staining method, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: James Felker; Other
Eligibility: 12 Months to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma (Skin)
Interventions: filgrastim, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation; Biological · Drug · Procedure
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 16 Years to 44 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Metastatic Melanoma
Interventions: MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumors
Interventions: ASP1951, pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more

Conditions: Neuroendocrine Tumors, Gynecologic Cancer
Interventions: Guarana, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors

Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Temozolomide in Treating Patients With Progressive Low-Grade Glioma

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

A Study of ASP1951 in Subjects With Advanced Solid Tumors

The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)